In a recent vaccine trial performed with African children, immunization with a recombinant
protein based on Plasmodium falciparum apical membrane antigen 1 (AMA-1) conferred a …

The Apical Membrane Antigen 1 (AMA-1) is considered a promising candidate for development
of a malaria vaccine against asexual stages of Plasmodium. We recently identified …

Vaccine development against Plasmodium vivax malaria lags behind that for Plasmodium
falciparum. To narrow this gap, we administered recombinant antigens based on P. vivax …

Paracoccidioidomycosis (PCM) is a systemic mycosis with lymphatic dissemination that is
caused by Paracoccidioides species. Treatment of PCM consists of chemotherapeutics such …

Plasmodium vivax is the most common species that cause malaria outside of the African
continent. The development of an efficacious vaccine would contribute greatly to control malaria…

Background Babesia bovis is a tick-transmitted protozoan hemoparasite and the causative
agent of bovine babesiosis, a potential risk to more than 500 million cattle worldwide. The …

Plasmodium vivax is the most widely distributed malaria species and the most prevalent
species of malaria in America and Asia. Vaccine development against P. vivax is considered a …

Fever is a regulated increase of the body temperature resulting from both infectious and non-infectious
causes. Fever is known to play a role in modulating immune responses to …

Malaria remains a global health challenge, necessitating the development of effective
vaccines. The RTS,S vaccination prevents Plasmodium falciparum (Pf) malaria but is ineffective …

Infections with Plasmodium vivax are predominant in the Americas, representing 75% of
malaria cases. Previously perceived as benign, malaria vivax is, in fact, a highly debilitating and …